<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698292</url>
  </required_header>
  <id_info>
    <org_study_id>67</org_study_id>
    <nct_id>NCT03698292</nct_id>
  </id_info>
  <brief_title>Itopride in Feeding Intolerance of Critically-ill Patients Receiving Enteral Nutrition</brief_title>
  <official_title>The Study of The Efficacy and Safety of Itopride For Feeding Intolerance in Critically-ill Patients Receiving Enteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will compare the effectiveness as well as the safety of Itopride against
      metoclopramide as the first line treatment for feeding intolerance in critically ill
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric Residual Volume</measure>
    <time_frame>7 days</time_frame>
    <description>Gastric residual volume as a surrogate to gastric emptying by means of gastric ultrasound.
of the study, at midpoint of the study and at the end of the study by guided ultrasonography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determining the adequacy of enteral nutrition</measure>
    <time_frame>24 hours</time_frame>
    <description>By calculating the ratio between administered and prescribed feeds over 24 hours duration (Percentage of feed goal tolerated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>3 months</time_frame>
    <description>Length of patients stay in the ICU will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Critically-ill Patients</condition>
  <arm_group>
    <arm_group_label>First group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride</intervention_name>
    <description>Prokinetic Drug</description>
    <arm_group_label>Second Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide 10mg</intervention_name>
    <description>Prokinetic Drug</description>
    <arm_group_label>First group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aging between 18 and 60 years (of both sexes) who are admitted to the ICU and
             are expected to stay in the ICU for not less than 7 days and are prescribed enteral
             feeding through naso- or oro-gastric tube whose modified nutritional risk in the
             critically ill (mNUTRIC) score is of more than or equal 5.

        Exclusion Criteria:

          -  Patients who met the following criteria were excluded:

               -  Age less than 18 years or more than 60 years.

               -  Previous upper gastrointestinal tract surgery, obstruction, hemorrhage or history
                  of GI disease.

               -  Clinically significant hepatic dysfunction. (&gt;3 times above the upper end of
                  normal range of bilirubin, Î³-glutamyl transferase, aspartate transaminase, or
                  lactate dehydrogenase)

               -  Regular use of H2 blockers, prokinetic, proton pump inhibitor or anticholinergic
                  agents for previous 4 weeks.

               -  Patients with arrhythmia or atrioventricular blocks.

               -  Any condition or comorbid disease that might interfere with gastric emptying such
                  as diabetes.

               -  Patients with head injuries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eman Elmokadem, MSc.</last_name>
    <phone>01006242110</phone>
    <email>emy_101_@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maha Gameel, MD</last_name>
    <phone>01227342966</phone>
    <email>mahagamil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Al Ainy Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Hanna, MD</last_name>
      <phone>01227342966</phone>
      <email>mahagamil@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Gholipour Baradari A, Alipour A, Firouzian A, Moarab L, Emami Zeydi A. A Double-Blind Randomized Clinical Trial Comparing the Effect of Neostigmine and Metoclopramide on Gastric Residual Volume of Mechanically Ventilated ICU Patients. Acta Inform Med. 2016 Dec;24(6):385-389. doi: 10.5455/aim.2016.24.385-389.</citation>
    <PMID>28077899</PMID>
  </reference>
  <reference>
    <citation>Gomes PC, Caporossi C, Aguilar-Nascimento JE, Silva AM, Araujo VM. Residual gastric volume evaluation with ultrasonography after ingestion of carbohydrate- or carbohydrate plus glutamine-enriched beverages: a randomized, crossover clinical trial with healthy volunteers. Arq Gastroenterol. 2017 Jan-Mar;54(1):33-36. doi: 10.1590/S0004-2803.2017v54n1-06.</citation>
    <PMID>28079236</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Future University in Egypt</investigator_affiliation>
    <investigator_full_name>Eman Mohamed El Mokadem</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

